I'm the Managing Director of Health Economics Consulting NZ (HECNZ), advising medtech and healthtech innovators on market access, HTA submissions, cost-effectiveness modelling, and reimbursement strategy across Australia, the UK, the US, Singapore, Japan, the EU, and Scandinavia. I'm returning to DHF after presenting on economic value in healthcare in 2025. On day 2, I'll be turning to a harder question: why clinically strong technologies still fail to land, and what good economic decisions look like along the way.